Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Covid-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Intravacc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 29, 2020

            Details:

            Covid-19 vaccine is based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc's prorietary Outer Membrane Vesicle (OMV) technology".

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Tel Aviv University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 13, 2020

            Details:

            The deal provides Neovii with the exclusive right to develop and commercialise a platform technology created by Biotechnology professor Jonathan Gershoni of TAU’s School of Molecular Cell Biology, to rapidly identify epitope-based vaccines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eicosapentaenoic Acid

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 14, 2020

            Details:

            EPAspire™ is shortly entering clinical trials as a promising candidate to treat patients with symptoms of the novel coronavirus infection. The MHRA in the UK has approved the trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tocilizumab,Tanezumab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 05, 2020

            Details:

            Chinese researchers recently registered a three-month clinical trial for Actemra that would recruit 188 coronavirus patients and take place from Feb 10 to May 10.